Young sick african guy with fever blowing his nose and checking body temperature with thermometer, lying on couch

Lilly BLAZE-1 COVID-19 Antibody Treatment Study

Ages

18 and Over

Location

Columbus, OH

Compensation

Up to $825*
Young sick african guy with fever blowing his nose and checking body temperature with thermometer, lying on couch

COVID-19 Antibody Treatment Trials in Columbus

Aventiv Research is currently participating in the Eli Lilly BLAZE-1 antibody COVID-19 treatment study at our Columbus, Ohio location. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the pandemic spread of coronavirus disease 2019 (COVID-19), which in critical cases results in pulmonary failure, respiratory complications, and death. There is an urgent need for effective therapeutics to modify disease outcomes. You can join the fight against COVID-19 by volunteering.

Enroll Now

Lilly BLAZE-1 COVID-19 Antibody Treatment Study

The primary objective of this clinical trial is to characterize the effect of an investigational drug, compared to placebo, on SARS-CoV-2 viral load and viral clearance.  You may qualify for this study if you have recently been diagnosed with COVID-19 or have one or more mild or moderate COVID-19 symptoms such as fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, or shortness of breath with exertion.

We are specifically looking for people who:

Are at least 18 years of age and satisfy at least one of the following at the time of screening:

  • Are at least 65 years of age
  • Have a BMI  ≥35
  • Have chronic kidney disease
  • Have type 1 or type 2 diabetes
  • Have immunosuppressive disease
  • Are currently receiving immunosuppressive treatment, or
  • Are ≥ 55 years of age AND have
    • cardiovascular disease, OR
    • hypertension, OR

OR

Are 12-17 years of age (inclusive) AND satisfy at least one of the following at the time of screening:

  • Have a BMI ≥85th percentile for their age and gender
  • Have sickle cell disease
  • Have congenital or acquired heart disease
  • Have neurodevelopmental disorders, for example, cerebral palsy
  • Have a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19)
  • Have asthma or reactive airway or other chronic respiratory disease
  • Have type 1 or type 2 diabetes
  • Have immunosuppressive disease, or
    • Are currently receiving immunosuppressive treatment

As a part of our ongoing commitment to protect your health and safety, we’re practicing enhanced safety measures at our clinical research sites.

Ready to Volunteer?

Volunteer today to see if you qualify for our COVID-19 monoclonal antibody (mAb) treatment study. *Qualified volunteers may be compensated for time and travel.